Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact.
about
PET/CT imaging of Mycobacterium tuberculosis infectionThe implications of whole-genome sequencing in the control of tuberculosisImpact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study MethodologiesIssues Related to the Updated 2014 Korean Guidelines for TuberculosisXpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States.Nuclear imaging: a powerful novel approach for tuberculosis.Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial.Performance evaluation of the Xpert MTB/RIF assay according to its clinical application.Comparison of Xpert MTB/RIF Assay and the Conventional Sputum Microscopy in Detecting Mycobacterium tuberculosis in Northern Thailand.Defining the needs for next generation assays for tuberculosisFluctuating Behavior and Influential Factors in the Performance of the QuantiFERON-TB Gold In-Tube Assay in the Diagnosis of Tuberculosis.Xpert®MTB/RIF for the Diagnosis of Tuberculosis in a Remote Arctic Setting: Impact on Cost and Time to Treatment Initiation.Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settingsDiagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIFInfectious Diseases (ID) Learning Unit: How Rapidly to Evaluate for Active Tuberculosis Disease in Low-Prevalence Settings.Use of Nucleic Acid Amplification Tests in Tuberculosis Patients in California, 2010-2013.Evaluation of the Cepheid Xpert MTB/RIF assay.Understanding the incremental value of novel diagnostic tests for tuberculosis.Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing.Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting.Reply to Baker and Holtom.Reply to El Sahly.Performance of Xpert MTB/RIF in induced sputum samples at detecting Mycobacterium tuberculosis.Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study.Assessment of Extrapulmonary Tuberculosis Using Gene Xpert MTB/RIF Assay and Fluorescent Microscopy and Its Risk Factors at Dessie Referral Hospital, Northeast Ethiopia
P2860
Q26748493-4B3CABFD-93F8-4169-A4ED-1C5EFC7B66E5Q26749040-083BA26A-12EE-4DA4-B1AD-FD1E35B4DEE8Q26767271-E96E82B2-B2D5-414F-A28A-BA9DB34FF767Q26771907-43BD9A88-B5A1-4570-B41B-FD5E76F0BCC4Q34048133-76A26D99-73A9-4198-B95A-44C709653EEBQ34315731-44605EEB-0C42-48D3-9EB5-FDE5FF0F2902Q34480176-80E2F91E-C2EB-4A6A-BA3C-F6E82EA6B137Q34584703-17F3DABD-B306-4C3B-8FBC-EFAD04A1D46AQ35603490-9BA49352-02AE-4BCF-99D6-D854E69C81F5Q35661898-2CFAAE87-91A9-490A-8AD6-E4BB9F11D398Q35749933-C57C3ACA-7CB1-4A29-B59F-5262CBB6104FQ35962293-3936C373-FC7F-44EC-A240-4EB7E33ECBC8Q36228816-C4C81ECF-8A02-4F1C-9C2D-C85F276A1907Q36353521-E720A0F2-B176-424A-8428-D2596287898BQ36900041-DECBBEFB-F8F0-4745-87B2-99B20CA6AD6EQ37487563-61944017-3E16-4D57-9BBF-B159517F0ADCQ38265418-E0270B9E-83CD-4B8B-AE9E-B0A5137C5E46Q40245352-90CFB5AF-C8BC-4A15-B322-F9453AF74DC4Q40341517-1D0A1E66-E42D-4241-BD92-28B166385BB8Q41546193-2BBF210D-3B50-4E88-9C46-85242C909635Q42708370-DDA7A85C-E29A-4099-A773-8A791004186FQ46912565-BB4E215B-1964-45EE-9A13-28F93B87764AQ51721863-DFA027C9-7344-4083-9B09-FFD5F140B1B4Q51846091-A708E33C-A2C4-4695-91F1-32819DE4A24BQ52355547-8385AD16-90CD-4389-858A-6A2DCAFF8DCDQ58797001-2384AFAA-60DB-4001-8696-6B5423FED98D
P2860
Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Xpert MTB/RIF testing in a low ...... accuracy and clinical impact.
@en
Xpert MTB/RIF testing in a low ...... accuracy and clinical impact.
@nl
type
label
Xpert MTB/RIF testing in a low ...... accuracy and clinical impact.
@en
Xpert MTB/RIF testing in a low ...... accuracy and clinical impact.
@nl
prefLabel
Xpert MTB/RIF testing in a low ...... accuracy and clinical impact.
@en
Xpert MTB/RIF testing in a low ...... accuracy and clinical impact.
@nl
P2093
P2860
P50
P356
P1476
Xpert MTB/RIF testing in a low ...... accuracy and clinical impact.
@en
P2093
Abebech D Aero
Andrei Dan
Fiona McIntosh
Hojoon Sohn
Kevin Schwartzman
Marcel Behr
P2860
P304
P356
10.1093/CID/CIU022
P407
P577
2014-01-14T00:00:00Z